Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and costeffectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies.
Uptake of next-generation sequencing (NGS) has increased dramatically due to significant cost reductions and broader community acceptance of NGS. To systematically review the evidence on both the clinical effectiveness and the cost-effectiveness of applying NGS to cancer care. A systematic search for full-length original research articles on the clinical effectiveness and costeffectiveness of NGS in MEDLINE and EMBASE. Articles that focussed on cancer care and involved the application of NGS were included for the review of clinical effectiveness. For the cost-effectiveness review, we only included the articles with economic evaluations of NGS in cancer care. We report the rate of successfully detecting mutations from the clinical studies.
The incremental cost-effectiveness ratio and sensitivity analysis outcomes are reported for the cost-effectiveness articles. Fifty-six articles reported that sequencing patient samples using targeted gene panels, and 83% of the successfully sequenced patients harboured at least 1 mutation. Only 6 studies reported on the cost-effectiveness of the application of NGS in cancer care. NGS is an effective tool for identifying mutation in cancer patients. However, more rigorous cost-effectiveness studies of NGS applied to cancer management are needed to determine whether NGS can improve patient outcomes cost-effectively.
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| INTRODUCTION
Cancer is a genetic disease driven by mutations. 1 Next-generation sequencing (NGS) is envisaged to have a significant impact on the mutation detection, management and treatment of cancer. [2] [3] [4] [5] [6] [7] Several studies have demonstrated that mutation analysis can assist clinicians to better classify tumours and prescribe suitable treatment programmes for patients. [8] [9] [10] [11] [12] [13] NGS has the potential to enable clinicians to simultaneously identify mutations, especially rare variants due to its sensitivity, in multiple genes that are known to commonly mutate into tumours. 14 To our best understanding, we are not aware of a systematic review of the effectiveness of NGS in detecting mutations as part of cancer care. This review will provide insights into the power of NGS in detecting mutations in patients' samples, among a wide range of cancer types.
An economic evaluation of new medical technologies shown to be effective is fundamental for health policy-makers so that they may be better informed about how best to allocate scarce resources. 15 Cost-effectiveness analysis (CEA) is the most common decisionassisting tool, where the costs and consequences or health benefits of a new intervention are compared against the existing regime.
Often, the result of the CEA is reported as the incremental cost for each unit of benefit gained from the new intervention, that is, the incremental cost-effectiveness ratio (ICER).
The overall aim of this study was to undertake a systematic review of studies on the clinical effectiveness and cost-effectiveness of using NGS in cancer management published from 2011 to 2017.
Clinical effectiveness is defined, in this review, as the mutation detection rate via NGS. Additionally, we also assess whether the outcome from NGS leads to a change in patient management, specifically, treatment with a molecular inhibitor to specifically target the identified genetic mutation, that is, targeted therapy. Quality of methodology and potential bias in studies are also assessed using the Joanna Table S1 in Appendix S1).
We did not specify search terms for comparison as we are comparing NGS against standard of care, and standard of care differs for each cancer type.
| Information sources
We searched MEDLINE and EMBASE for original research articles on the clinical effectiveness of NGS in cancer care, written in English and published from January 2011 to July 2017. MEDLINE and EMBASE were chosen as together they are collectively the largest database for medical research, and both databases complement each other in terms of the search results. 18 The field has undergone significant change in the past 6 years, therefore, we have chosen to review articles from 2011.
| Study selection
The inclusion criteria consisted of original articles that focussed on cancer care and involved the application of gene sequencing; English language articles. Reviews, Editorials, Conference Abstracts, Case
Reports, or Methods articles were excluded from our review.
| Data items
We extracted from each study: the number of patients who were sequenced for mutations (either germline and/or somatic); the number of patients with at least 1 mutation detected by the technology; the number of patients identified with at least 1 actionable mutation (actionable as defined in individual articles); and number of patients who proceeded to receive targeted therapy as a result of the NGS outcome (change in management).
| Appraisal of individual studies
All reviewed studies were appraised using JBI Critical Appraisal
Checklist for Diagnostic Test Accuracy Studies.
16,17
| Summary measures
We measure the effectiveness of NGS applied to cancer care by evaluating the state of current evidence reported in the reviewed articles, including the weighted average of the proportion of successfully sequenced patients, the proportion of successfully sequenced patients with at least 1 mutation, the proportion of successfully sequenced patients with actionable mutation, the proportion of patients who proceeded to receive targeted therapy. In addition, we also reported the main reasons for participants not proceeding to receive targeted therapy. cost, cost-benefit analysis, or CEA (detailed in Table S2 in Appendix S1).
| Information sources
We searched MEDLINE and EMBASE for original research articles on the cost and cost-effectiveness of NGS in cancer care, written in English and published from January 2011 to July 2017.
| Study selection
The inclusion criteria consisted of original articles that focussed on cancer and involved the application of NGS; English language articles;
articles that provided a measure of relative economic value such as cost, cost-effectiveness or cost-to-utility ratio or net benefit/benefitto-cost ratio through the application of NGS. Reviews, Editorials, Conference Abstracts, Methods articles or studies without an economic evaluation were all excluded.
| Data items
From the cost analysis articles reviewed, we recorded, from each study, cost of providing the NGS service (including labour, supplies, and overhead administration), and the downstream cost of the intervention following the NGS outcome. From the CEA articles, we analysed the model and the ICER. A model creates the framework for the analysis, in this case, allowing investigators to determine the costs and effects of the interventions. The output of the model can be used to determine the ICER, a ratio that measures the incremental costs incurred by one alternative over another compared to the additional effects. 15 Generally, the formula to calculate ICER is
We also recorded the variables that significantly influenced the ICER as reported by the authors.
| Appraisal of individual studies
Cost-effectiveness studies were evaluated in terms of their model robustness, and the quality of inputs into the specific model using the framework developed by the Good Practice Guidelines for DecisionAnalytic Modelling in Health Technology Assessment. 19 
| Summary measures
We estimated an average cost for providing the NGS service and expressed in 2016 real US dollars. All costs reported in the selected studies were inflated to 2016 by country-specific consumer price index (CPI) published by the Organisation for Economic Co-operation and Development (OECD) 20 and all non-US$ currency were converted into US$ using both (1) the 2016 yearly average exchange rate published by the Internal Revenue Service, 21 and (2) Purchasing Power Parity published by the OECD. 22 The sensitivity analyses reported in the studies were also assessed in order to identify common variables that have a significant effect on the ICER. A total of 21 823 patients had their tissue sequenced using NGS.
Forty-five articles studied somatic mutations in tumour tissues, and the remaining 11 articles analysed both germline and somatic mutations. In general, around 90% of the tissues were successfully sequenced, and 83% of the successfully sequenced samples were identified to have at least 1 mutation via the use of targeted gene panel sequencing (Table 1 ). Similar detection rates were also reported in studies that performed whole exome sequencing (WES) and RNA sequencing.
We also note that there is a diverse definition of "actionable vari- Table S3 in Appendix S1).
| Assessing the effectiveness of NGS that leads to change in management
One of the benefits of molecular profiling by NGS is that it can be used to inform clinicians whether a genetic mutation treatable with a pharmaceutical drug was identified. Twenty-four articles reported patients having received targeted therapy based on the NGS analysis outcome. Within these 24 articles, 37% of the patients proceeded to receive therapy matching their genetic profile. Excluding patients who harboured a mutation that could not be targeted with available drugs, the reasons reported for not giving patients targeted therapy were: (1) the patients were either stable or responding to current treatment or there was no active disease; (2) the patients did not meet eligibility criteria to be enrolled in clinical trials; (3) the patient's disease was too advanced or they did not survive or the patient's condition deteriorated; and (4) the patient could not access suitable clinical trials (eg, due to geographical distance, or treatment ineligible for insurance cover).
| Assessing bias in the studies
We used the JBI Critical Appraisal Checklist for Diagnostic Test Accuracy Studies to assess for potential bias in each study ( Figure S1 in Appendix S1). Sixty-eight percent of the studies used either randomly selected samples or consecutive samples in the sequencing analysis.
Ninety percent of the studies avoided the case-control study design, which indicated that the studies were less likely to suffer from selection bias. 16, 17 Eighty-seven percent of the studies did not perform reference tests, for example, Sanger sequencing or histopathology.
| Cost analysis of NGS
In our review of cost analysis reports on NGS, we found 6 articles reporting cost of NGS ( Figure 2 ). We also extracted the cost of NGS reported in the other 6 cost-effectiveness studies (Table 2A) . Costing methods used in these reports varied widely. On average, the cost of targeted gene panel sequencing per sample was found to be US $1609 (range: US$488-US$3443). Cost of sequencing is generally lower if it is performed in-house [25] [26] [27] compared to outsourcing to a service provider. [28] [29] [30] 32 Two articles reported cost of WES and RNAseq. Mody et al reported the total cost of WES and RNAseq to be US $5938. 34 Oberg et al reported the cost of WES to be US$4459 and the cost of RNAseq to be US$1764. 35 Based on the results from Haslem et al reported the cost of management, from NGS sequencing to targeted therapy and the total cost per patient to be around US$90 000 for the targeted therapy group (Table 2B) . 24 
| Cost-effectiveness of NGS in cancer care
Our search for cost-effectiveness studies on NGS in cancer care yielded 2037 articles. Only 6 articles included cost-effectiveness studies of the application of NGS (targeted gene panel) in cancer. The 6 articles reporting cost-effectiveness were selected for full text review ( Figure 2 ). We also evaluated the quality of the studies against the Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment. 19 Our assessment showed that the modelling approaches were appropriate, however, modelling outcomes could be further improved with more data on the health effects of targeted therapy (Table S4 in Appendix S1).
The 6 selected reports could be separated into 2 types. Three of the articles assessed the cost-effectiveness of recommending patients receiving targeted therapy matching their genetic mutation identified via NGS; and the remaining 3 articles assessed the costeffectiveness of using NGS as part of the screening program to direct patients or high risk family members into prophylactic treatment or closer surveillance.
Two out of 3 articles in the "targeted therapy" group reported that NGS and targeted therapy was not cost-effective (Table 3A) , using an ICER threshold of US$100 000 per Quality Adjusted Life Year (QALY) gained. An ICER of less than US$100 000/QALYs gained is generally considered favourable for funding in the United States. 36 Li et al undertook decision tree modelling to compare the costeffectiveness of an NGS panel of 34 genes vs the BRAF V600 singlesite mutation test using data on metastatic melanoma patients. strategy, that is, using NGS to identify mutation and assigning
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Article include for full review, N=79 is, all patients received cytotoxic therapy, and the authors concluded that the targeted therapy strategy was not cost-effective.
Two out of the 3 articles in the "screening" group reported that the use of NGS was cost-effective (Table 3B) , that is, under US $100 000 per QALY gained. Gallego et al evaluated the costeffectiveness of screening for Lynch syndrome using 4 types of NGS sequencing panels, and compared current standard diagnostic care
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FIGURE 2 PRISMA-style flow diagram illustrating cost-effectiveness article selection process Table 3B ). 33 In colorectal cancer patients, returning incidental findings were expected to result in a gain of 25.4
QALYs per 100 000 patients. The ICERs were estimated to be US $115 000 per additional QALY gained for returning incidental findings to colorectal cancer patients.
| Variables that have a significant effect on the ICERs for NGS compared with standard care
For the 3 articles that evaluated cost-effectiveness of using NGS and targeted therapy in cancer patient management, the significant factors for the ICER were: the cost of the drug (specialized molecular inhibitor), followed by the health benefit from the intervention. Interestingly, cost of sequencing did not have a significant effect on the ICER (Table S5A in Appendix S1).
For the 3 articles that evaluated cost-effectiveness of using NGS as part of the screening program, significant factors for the ICERs were: disease penetrance in patients with pathogenic variants, followed by the probability of having the pathogenic variant, cost of sequencing, and the proportion of patient/family members accepting the recommendation (eg, prophylactic mastectomy, or genetic counselling and closer surveillance; Table S5B in Appendix S1).
| DISCUSSION
We evaluated the effectiveness of NGS technology by systematically reviewing studies on the use of NGS technology in molecular profiling of patient samples. A wide range of cancer types and sequencing methods were reported in the reviewed articles. The majority of the reviewed articles profiled patients' samples by sequencing a panel of cancer-related genes. Only 5 articles used WES to sequence patients' samples. We found that 83% of successfully sequenced samples were identified to have at least 1 mutation via the usage of targeted gene panel sequencing. We also found that 37% of the patients proceeded to receive therapy based on their genetic profile.
Most of the studies that we evaluated did not perform reference tests, for example, Sanger sequencing. Nevertheless, we are not highly concerned about this as NGS is proven to have high sensitivity and specificity, and there is a high concordance between the Sanger sequencing and NGS outcome, 38 thus it is not necessary to perform an orthogonal validation assay.
In assessing the evidence of NGS outcomes leading to the downstream use of targeted therapy, we conclude that commonly reported limiting factors of targeted therapy are the availability and effectiveness and/or specificity of molecular inhibitors, the heterogeneity of the disease, cost, and other limitations (e.g. geographical, or physical condition) to access targeted therapy, which is consistent with other study findings. 39, 40 A number of other targeted therapy and/or precision medicine trials were reported but not included in our review because they did not use NGS as part of the treatment plan. 37, 41 Currently, there are a number of well-designed and large scale clinical trials for precision medicine in cancer, [42] [43] [44] [45] and we believe the outcome from these studies will have significant impacts on our current understanding of the benefit of NGS and targeted therapy in cancer care.
A recently published scoping review by Douglas et al suggested that sequencing for ACMG recommended clinically actionable genes in Lynch syndromes, hereditary breast and ovarian cancer, and multiple endocrine neoplasia type 2 were cost-effective. 46 However, the evidence presented in the review focussed only on the earlier tech- We note that the probability of detecting mutations and actionable mutations varied across studies as a result of different sequencing methods, and the definition of actionable mutations used in the studies. We maintain that for reports to be comparable, researchers should adopt published guidelines or widely accepted standards in reporting actionable variants. 47 We were unable to estimate variation in the rate of detecting mutations that arise due to the heterogeneity of sequencing approaches used in the reviewed studies.
The possibility of truly achieving precision medicine as a treatment option for cancer has become more promising with the announcement of US$1000 whole genome sequencing by Illumina. 48 Readily available and cost-effective gene sequencing will likely become a valuable tool in achieving precision medicine treatment options, especially for cancer patients, where genetic mutations play a critical role in the onset of the disease. 49 However, there remains a number of issues needing attention with regard to the application of NGS technology for the treatment of cancer in current healthcare systems, such as the effectiveness of molecular targeted therapy based on patients' genetic information, 50 and the reimbursement of the costs. 51 These concerns are beginning to be addressed, but there is a need for a more robust and comprehensive economic evaluations of NGS technology as a diagnostic option in cancer care.
In our search for evidence of cost-effectiveness of NGS in clinical applications for cancer patients, we found only 6 articles that We note that these 2 groups of models produced different ICERs and different sets of factors that have significant effects on ICERs. In the targeted therapy group, the cost of treatment is significantly higher than the cost of NGS, therefore, has a more pronounced effect on the ICER. This finding highlighted that, in general, the cost of targeted therapy needs to be significantly reduced for the use of NGS in cancer management to become cost-effective in this context. In the "screening" group, the cost of downstream interventions, that is, prophylactic mastectomy, or genetic counselling, are much lower compared to the cost of specialized drugs used in the targeted therapy.
Consequently, cost of sequencing, and the probability of detecting a pathogenic variants became significant variables for explaining the
ICERs.
There are a number of limitations in the current body of evidence. Firstly, none of the studies used actual clinical data in their modelling. Assumptions were made based on published studies only, and included items such as the rate of using particular treatment strategies in the population, which may not be representative of typical treatment events. Events such as complications arising from side effects will influence the model accuracy as they have not been captured in the current models. In addition, the models imputed cost information from government or laboratory sources rather than using individual or patient costs. Secondly, the cost of the infrastructure required to support NGS, including bioinformatics analysis, and training provided for clinicians to utilize such NGS information were not always included in the models. Furthermore, the reports in the "targeted therapy" group did not take into account the potential health state utility gained from averting unnecessary cytotoxic therapy or treatment-related toxicity, which may have improved costeffectiveness. Four out of 6 of the cost-effectiveness reports used US$100 000 as the ICER threshold (Doble et al used AU$200 000; Li et al did not report an ICER threshold). We believe that the use of such a threshold, although convenient, is insufficient to determine whether the use of NGS in clinical settings is economically viable.
| CONCLUSIONS AND FUTURE RESEARCH
In our evaluation of the effectiveness of NGS, we found that NGS is effective at identifying mutations in cancer patients, and we reported that 37% of the diagnosed patients proceeded to receive therapy matching their genetic profile. However, with only 6 articles available that assess the cost-effectiveness of NGS in various settings, it remains an area for future research to determine whether the technology is cost-effective in routine cancer management.
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